Abion Inc. (203400)
Market Closed
5 Dec, 06:30
KRX SM KRX SM Primary ₩
3,825. 00
-225
-5.56%
₩
108.88B Market Cap
- P/E Ratio
0% Div Yield
1,216,778 Volume
- Eps
₩ 4,050
Previous Close Day Range
3,725 4,080
Year Range
1,911.11 7,277.78
Want to track 203400 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
203400 closed today lower at ₩3,825, a decrease of 5.56% from yesterday's close, completing a monthly increase of 36.61% or ₩1,025. Over the past 12 months, 203400 stock lost -46.5%.
203400 is not paying dividends to its shareholders.
Abion Inc. has completed 1 stock splits, with the recent split occurring on Dec 01, 2025.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on KRX SM (KRW).
Abion Inc. (203400) FAQ
What is the stock price today?
The current price is ₩3,825.00.
On which exchange is it traded?
Abion Inc. is listed on KRX SM.
What is its stock symbol?
The ticker symbol is 203400.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0%.
What is its market cap?
As of today, the market cap is 108.88B.
Has Abion Inc. ever had a stock split?
Abion Inc. had 1 splits and the recent split was on Dec 01, 2025.
Abion Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Young-Gi Shin CEO | KRX SM Exchange | - ISIN |
| South Korea Country | 48 Employees | - Last Dividend | 1 Dec 2025 Last Split | - IPO Date |
Overview
ABION Inc. is a South Korean biopharmaceutical company with a global presence, focusing on the discovery, development, and commercialization of innovative anticancer therapeutics. Founded in 2007 and headquartered in Seoul, South Korea, ABION Inc. leverages cutting-edge science and technology to create novel treatments aimed at improving the outcomes and quality of life for patients battling cancer and infectious diseases. By conducting rigorous clinical trials and pursuing advanced research in biotechnology, ABION Inc. has established itself as a leader in the pharmaceutical biotech industry, with a particular emphasis on targeted therapies and immune-modulating agents.
Products and Services
- ABN401 - A tyrosine kinase inhibitor currently in Phase II clinical trials for the treatment of non-small cell lung cancer and in Phase I for breast cancer. ABN401 represents a promising advance in targeted cancer therapy, focusing on disrupting the signaling pathways that drive tumor growth and progression.
- ABN501 - A human monoclonal antibody targeting claudin 3, under investigation for the treatment of solid cancers. ABN501's mechanism aims to neutralize specific proteins involved in tumor cell adhesion and migration, potentially inhibiting cancer spread.
- ABN201 - An antibody cytokine fusion protein designed to target solid cancers. This innovative treatment combines the specificity of targeted antibodies with the cancer-fighting properties of cytokines to stimulate the patient's immune response against the tumor.
- ABN101 - A dry powder inhaler developed as a prophylactic treatment for various respiratory viruses. By delivering medication directly to the lungs, ABN101 aims to provide rapid and effective protection against viral infections, potentially reducing the impact of outbreaks and pandemics.
- ABN701 - Currently under development for SEBI infectious diseases. ABN701 exemplifies ABION Inc.'s commitment to extending its research and development framework beyond cancer to address critical needs in infectious disease management.
- ABN 901, ABN 902, and ABN 903 - A series of products in the pipeline addressing infectious diseases related to biological disasters. These interventions highlight ABION Inc.'s strategic initiative to develop therapies that can mitigate the consequences of biological threats and help safeguard public health.
Contact Information
Address: Hanhwa Biz Metro Bldg
Phone: 82 2 6006 7657
Website: https://abionbio.com
2025 © Marketlog. All Rights Reserved.
